Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Fagron shareholders approve all proposed resolutions

Posted on: 15 May 18

Nazareth (Belgium) / Rotterdam (The Netherlands), 15 May 2018
Regulated information

Fagron announces today that the annual general meeting of shareholders and the extraordinary shareholders meeting, both held on 14 May 2018, have adopted all proposed resolutions.

The meeting approved, amongst other things, the 2017 financial statements and declared a dividend of € 0.10 per share for the year 2017. The shareholders have also discharged the directors and the statutory auditor who were active during the 2017 financial year. The meeting also approved the co-optation by the board of directors of Management Deprez BVBA, permanently represented by Veerle Deprez, as an independent non-executive director and the co-optation of Rafael Padilla as an executive director. Furthermore, the meeting decided to reappoint Rafael Padilla and Karin de Jong as executive directors for a period of four years. Management Deprez BVBA, permanently represented by Veerle Deprez, was reappointed as an independent non-executive director for a period of four years.

Fagron is paying a gross dividend of € 0.10 per share (coupon number 10). This is a net dividend of € 0.07 per share; being the gross dividend less 30% Belgian dividend withholding tax.

The calendar is as follows:
18 May   Ex-dividend date
21 May   Record date
22 May   Dividend available for payment

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Please open the link below for the press release:



Last updated on: 15/05/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.